Buvidal 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
R/0021 
Renewal of the marketing authorisation. 
25/05/2023 
26/07/2023 
SmPC and PL 
IA/0020/G 
This was an application for a group of variations. 
09/11/2022 
n/a 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
parameter) 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IB/0019/G 
This was an application for a group of variations. 
05/10/2022 
n/a 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
IB/0018/G 
This was an application for a group of variations. 
04/03/2022 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0016/G 
This was an application for a group of variations. 
05/11/2021 
n/a 
B.II.c.2.d - Change in test procedure for an excipient 
- Other changes to a test procedure (including 
replacement or addition) 
B.II.c.1.b - Change in the specification parameters 
and/or limits of an excipient - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.II.c.2.d - Change in test procedure for an excipient 
- Other changes to a test procedure (including 
replacement or addition) 
B.II.c.1.a - Change in the specification parameters 
and/or limits of an excipient - Tightening of 
specification limits 
B.II.c.1.b - Change in the specification parameters 
and/or limits of an excipient - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.II.c.z - Change in control of excipients in the 
Finished Product - Other variation 
II/0015/G 
This was an application for a group of variations. 
23/09/2021 
13/09/2022 
SmPC 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/459/2
Periodic Safety Update EU Single assessment - 
25/03/2021 
19/05/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02007 
buprenorphine (all formulations except implants) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/459/202007. 
X/0008/G 
This was an application for a group of variations. 
25/03/2021 
19/05/2021 
SmPC, Annex 
II, Labelling 
and PL 
Annex I_2.(c) Change or addition of a new 
strength/potency 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0013/G 
This was an application for a group of variations. 
27/10/2020 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0012 
B.II.e.2.z - Change in the specification parameters 
26/10/2020 
n/a 
and/or limits of the immediate packaging of the 
finished product - Other variation 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0011 
B.II.e.7.b - Change in supplier of packaging 
05/10/2020 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IAIN/0010 
C.I.z - Changes (Safety/Efficacy) of Human and 
17/09/2020 
19/05/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IB/0009 
B.II.g.5.b - Implementation of changes foreseen in 
08/09/2020 
n/a 
an approved change management protocol - 
Requires further supporting data 
II/0007/G 
This was an application for a group of variations. 
18/06/2020 
19/05/2021 
SmPC 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
storage conditions of the finished product - Other 
variation 
IB/0006 
C.I.z - Changes (Safety/Efficacy) of Human and 
04/03/2020 
n/a 
Veterinary Medicinal Products - Other variation 
II/0005 
B.II.d.1.e - Change in the specification parameters 
13/02/2020 
n/a 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
IB/0004 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
13/12/2019 
12/06/2020 
SmPC 
storage conditions of the finished product - Other 
variation 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0003/G 
This was an application for a group of variations. 
29/11/2019 
n/a 
B.II.d.2.b - Change in test procedure for the finished 
product - Deletion of a test procedure if an 
alternative method is already authorised 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
II/0002 
B.II.g.2 - Introduction of a post approval change 
12/09/2019 
n/a 
management protocol related to the finished product 
IB/0001 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
21/06/2019 
12/06/2020 
SmPC 
storage conditions of the finished product - Other 
variation 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
